http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a69a0b71080610775d42721de65133df
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Capella |
| name | Gabriel Capella |
| given-name | Gabriel |
| organization-name | 3Translational Research Laboratory, IDIBELL-Catalan Institute of Oncology, Barcelona, Spain; and Hereditary Cancer Program, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), ONCOBELL Program, L’Hospitalet de Llobregat, Barcelona, Spain; Consortium for Biomedical Research in Cancer – CIBERONC, Carlos III Institute of Health, Madrid, Spain University of Barcelona Barcelona Spain 1Hereditary Cancer Program, Catalan Institute of Oncology (ICO - IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; 4CIBERONC, Instituto de Salud Carlos III, Madrid, Spain. Authors' Affiliations: 1Environmental Health Sciences, 2Department of Otorhinolaryngology, 3Department of Internal Medicine, 4Department of Human Genetics, and 5Department of Epidemiology, School of Public Health and 6Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan; 7Biostatistics and Bioinformatics Unit and 8Translational Research Laboratory, Catalan Institute of Oncology-IDIBELL, Barcelona, Spain; and 9Department of Community Medicine, Carmel Medical Center, Technion Institute of Technology, National Israeli Cancer Control Center, Haifa, Israel Authors' Affiliations: 1Departament de Biologia Cel·lular, Immunologia i Neurociències, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Facultat de Medicina, Universitat de Barcelona; 2Hereditary Cancer Program, Translational Research Laboratory, Catalan Institute of Oncology, ICO-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Gran Via 199-203, 08907- L'Hospitalet de Llobregat, Llobregat; 3Servei d'Anatomia Patològica i Institut de Recerca Biomèdica de Lleida, Lleida, Spain 1Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain. a Translational Research Laboratory, IDIBELL, on behalf of Program of Applied Radiobiology of Catalonia (PRACAT), Spain Catalan Institute of Oncology, 08907 Barcelona, Spain; and Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain;; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL. Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain Authors' Affiliations: 1Translational Research Laboratory, Catalan Institute of Oncology - Bellvitge Biomedical Research Institute (IDIBELL); 2Cancer Epigenetics and Biology Program (PEBC); 3Department of Pathology, Hospital Universitari de Bellvitge; 4Department of Medical Oncology, Catalan Institute of Oncology; 5Department of Gynecology, Hospital Universitari de Bellvitge, Barcelona; and 6Department of Research and Development (R&D), PharmaMar S.A, Madrid, Spain Institut d'Investigació Biomèdica de Bellvitge-Institut Català d'Oncologia Gran Via km 2.7, Hospitalet, 08907 Barcelona, Spain; 6Translational Research Laboratory, IDIBELL-Catalan Institute of Oncology, Barcelona, Spain; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. Sanne W. ten Broeke, Heleen M. van der Klift, Carli M.J. Tops, Manon Suerink, Frederik J. Hes, Hans F.A. Vasen, Juul T. Wijnen, and Maartje Nielsen, Leiden University Medical Center, Leiden; Encarna Gomez Garcia, Maastricht University Medical Center, Maastricht; Nicoline Hoogerbrugge, Arjen R. Mensenkamp, and Liesbeth Spruijt, Radboud University Medical Center, Nijmegen; Tom G.W. Letteboer, University Medical Center, Utrecht; Theo A.M. van Os and Egbert J.W. Redeker, Academic Medical Center; Liselotte... 13Translational Research Laboratory, Catalan Institute of Oncology, Barcelona, Spain. 3Translational Research Laboratory, Institut Catala d'Oncologia, Barcelona, Spain; 2Traslational Research Laboratory, ICO-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; 14Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Spain.; 19CIBERONC Instituto de Salud Carlos III, Spain. From the Institut Català d'Oncologia–Biomedical Research Institute of Bellvitge, L'Hospitalet de Llobregat; University of Barcelona, Barcelona, Spain; Agendia; Netherlands Cancer Institute; Slotervaart Hospital, Amsterdam; Leiden University Medical Center, Leiden, the Netherlands; and University of Oxford, Radcliffe Infirmary, Oxford, United Kingdom. Hereditary Cancer Program Institut Catala d'Oncologia‐IDIBELL, L'Hospitalet de Llobregat Barcelona Spain From the Department of Cancer and Metastasis, Institut de Recerca Oncològica, Hospital Duran i Reynals; Department of Medical Oncology, Laboratori d'Investigació Gastrointestinal, Institut de Recerca; Department of Pathology, Hospital de Sant Pau; and Institut Català d'Oncologia, L'Hospitalet, Barcelona, Spain. Hereditary Colorectal Cancer Programme, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Catalonia, Spain |
Incoming Links
Showing number of triples: 1 to 116 of 116.